- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03342482
Glutamate Neuro-Excitotoxicity in GWI (GWI)
The objective of the proposed research is to examine whether dietary exposure to food additives containing glutamate may be contributing to symptoms in Gulf War Illness (GWI). The rationale for proposed study comes from data in the fibromyalgia field which suggests that reducing the consumption of dietary glutamate can reduce over-excitation in the nervous system, leading to symptom improvement. In prior research, a low-glutamate diet (restricting food additive consumption) was tested in fibromyalgia patients. After one-month on the diet, 84% of patients had >30% of their symptoms go away (with 11 symptoms remitting on average), and 8 subjects had complete remission of all symptoms. Subjects then had a significant return of symptoms upon challenge with monosodium glutamate (MSG) as compared to placebo. Since there is almost complete symptom overlap between fibromyalgia and GWI, it is of utmost importance to test this diet as a low-cost treatment option in GWI patients.
The findings from this research will ultimately be applicable to all GWI patients and potentially to other veterans with a similar symptom profile as well. The ultimate impact of this research could be quite profound, as it has the potential to impact all of the symptoms of GWI, as opposed to being a proposed treatment for only one of the symptoms. This dietary treatment has been shown to dramatically affect symptoms like fatigue, cognitive dysfunction, and pain; and thus, has the potential to dramatically improve quality of life for these individuals. Potential benefits of the treatment are great, and risks are minimal, as the treatment involves shifting the diet to a healthier, whole-food approach.
First, the study will confirm or negate the idea that abnormal glutamate signaling in the nervous system could be causing symptoms in GWI. Second, if found to be successful, then this will provide a low-cost, easy-to-implement treatment option for the many veterans suffering from this multi-symptom illness. Third, this research could lead to future studies to identify potential causes of this abnormal neurotransmission, to help prevent future illness onset.
Study Overview
Detailed Description
Objective/ Hypothesis: The objective of this clinical trial is to test the effectiveness of a low-glutamate diet in GWI patients, as a way to mediate symptom occurrence by reducing excess glutamatergic neurotransmission.
Specific Aims:
Aim 1- Determine if GWI is a glutamate neurotoxicity disorder, by testing whether reduced exposure to dietary glutamate can modulate symptoms. Hypothesis: Dietary glutamate restriction will significantly reduce GWI symptoms, including fatigue, cognitive dysfunction, pain, problems sleeping, headache/migraine, and diarrhea; as measured by symptom questionnaire, dolorimetery, computerized cognitive testing, EEG and fMRI memory testing. Additionally, brain glutamate levels will be reduced after one month on the diet, as measured by magnetic resonance spectroscopy (MRS).
Aim 2- Confirm that altered dietary glutamate exposure was the cause of symptom improvement.
Hypothesis: Challenge with MSG, as compared to placebo, in a randomized, double-blind, placebo-controlled crossover challenge, will significantly increase the occurrence of symptoms, cause increased pain sensitivity as measured by dolorimetry, increased excitatory neurotransmission as measured by EEG, and a worsening of cognitive function as measured by computerized cognitive testing.
Study Design: 40 subjects will be recruited from around the US . After phone screening, eligible individuals will travel to Washington DC for their first visit, where subjects will undergo baseline testing, including assessment of symptoms, cognition, brain glutamate levels and working memory testing using fMRI. For phase 1, subjects will be randomized to a low-glutamate diet (n=20) or a waitlisted group (n=20 as controls), and symptom occurrence will be compared after one month. Waitlisted participants will follow the low-glutamate diet over the following month. At the end of phase 1, subjects will return to DC, will undergo post-diet assessment of symptoms (same as baseline), and then will move onto Phase 2 of the study, a randomized, double-blind, placebo-controlled crossover challenge, to test whether symptoms recur upon challenge with MSG and not with placebo. Subjects will be randomized as to which contingency (MSG or placebo) is received first, and will receive MSG for 3 consecutive days on one of the weeks and placebo for 3 consecutive days on the other week. Symptoms, EEG and cognition will be assessed on day 3 of challenges each week. All subjects will still be following the low-glutamate diet during the challenge period, so their only exposure to glutamate will be from the week they receive the MSG.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- American University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males & Females
- Served (and was deployed) in the Persian Gulf War
- Fulfill both Kansas and CDC definitions of GWI
- Stable medication regimen for 3 or more months
Exclusion Criteria:
- Active Duty Military
- Current substance use disorder
- Unwilling to change diet for 2 months
- Severe asthma requiring past hospitalization
- Seizure disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
5 g of placebo (sugar and salt) will be administered in veggie capsules
|
The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
|
Experimental: MSG
5 grams of MSG will be administered in veggie capsules
|
The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom Score Change
Time Frame: Baseline, 1 month, 5th week, 6th week
|
The number and type of symptoms will be assessed with a symptom score measure
|
Baseline, 1 month, 5th week, 6th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive Function
Time Frame: Baseline, 1 month, 5th week, 6th week
|
A computerized cognitive battery will measure cognitive function
|
Baseline, 1 month, 5th week, 6th week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in EEG
Time Frame: Baseline, 1 month, 5th week, 6th week
|
Electroencephalography will be used to measure brain excitation
|
Baseline, 1 month, 5th week, 6th week
|
Change in Brain Glutamate Levels
Time Frame: Baseline, 1-month
|
Brain glutamate levels will be measured using magnetic resonsnance psectroscopy
|
Baseline, 1-month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kathleen F Holton, PhD, American University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-2017-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gulf War Syndrome
-
American UniversityBoston University; Massachusetts General Hospital; Georgetown University; Nova...RecruitingGulf War Syndrome | Gulf War IllnessUnited States
-
Roskamp Institute Inc.Boston University; United States Department of Defense; Palo Alto Veterans Institute...Recruiting
-
University of UtahVA Salt Lake City Health Care SystemWithdrawn
-
Baylor College of MedicineTexas A&M University; Michael E. DeBakey VA Medical CenterNot yet recruiting
-
Nova Southeastern UniversityBoston University; Weill Medical College of Cornell University; RTI InternationalRecruiting
-
Georgetown UniversityU.S. Army Medical Research and Development CommandCompletedGulf War Illness | Persian Gulf War SyndromeUnited States
-
South Florida Veterans Affairs Foundation for Research...Unknown
-
VA Office of Research and DevelopmentCompleted
-
University of Alabama at BirminghamCongressionally Directed Medical Research ProgramsRecruiting
-
Baylor College of MedicineMichael E. DeBakey VA Medical CenterTerminated
Clinical Trials on Low-glutamate diet
-
American UniversityChildren's National Research InstituteCompletedRandomized Controlled Trial | Refractory Epilepsy | Diet Intervention | Epilepsy in Children | Epilepsy in YouthUnited States
-
Oregon Health and Science UniversityUniversity of ArizonaCompletedIrritable Bowel Syndrome | FibromyalgiaUnited States
-
Burke Rehabilitation HospitalCompletedStroke | Ischemic StrokeUnited States
-
Cedars-Sinai Medical CenterRecruitingImplementing a Low Fiber Diet vs. Regular Diet in Postoperative Colorectal Patients With IleostomiesIleostomy; Complications | Bowel Obstruction | Postoperative IleusUnited States
-
Queen's UniversityTerminatedObesity | Cardiovascular Disease | Metabolic SyndromeCanada
-
Boston Children's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Brigham...Completed
-
Region StockholmRecruitingDiabetes Mellitus Type 2 in ObeseSweden
-
Albert Einstein College of MedicineRobert C. Atkins FoundationCompletedType 2 DiabetesUnited States
-
Tulane University Health Sciences CenterCompletedCardiovascular Diseases | Obesity | Body Composition | Blood PressureUnited States